Post by Medipol University

Our faculty member Dr. Yasemin Yozgat Byrne from the International School of Medicine has developed an invention that may contribute to predicting treatment response and resistance development in cancer. The invention has been granted a patent by the United States Patent and Trademark Office (USPTO). The patent, titled “Hexokinase 1 Isoform B for Use as a Prognosis Marker and Specific Target Against Cancer,” targets the HK1b isoform specific to cancer cells. The studies conducted by Dr. Yasemin Yozgat Byrne and her team are expected to contribute to personalized treatment approaches and the development of new drugs, while also demonstrating our University’s research strength in cancer biology and precision medicine at the international level.